These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39262344)

  • 1. Naloxone Dispensing to Youth Ages 10-19: 2017-2022.
    Terranella A; Guy G; Mikosz C
    Pediatrics; 2024 Oct; 154(4):. PubMed ID: 39262344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.
    Sohn M; Talbert JC; Huang Z; Lofwall MR; Freeman PR
    JAMA Netw Open; 2019 Jun; 2(6):e196215. PubMed ID: 31225895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
    Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
    MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018.
    Barenie RE; Gagne JJ; Kesselheim AS; Pawar A; Tong A; Luo J; Bateman BT
    Drug Saf; 2020 Jul; 43(7):669-675. PubMed ID: 32180134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Cost Sharing and Naloxone Prescription Dispensing.
    Chua KP; Conti RM; Lagisetty P; Bohnert AS; He S; Nguyen TD
    JAMA; 2024 Jul; 332(2):124-132. PubMed ID: 38869887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine Dispensing Among Youth Aged ≤19 Years in the United States: 2015-2020.
    Terranella A; Guy GP; Mikosz C
    Pediatrics; 2023 Feb; 151(2):. PubMed ID: 36691760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between a State Law Allowing Pharmacists to Dispense Naloxone Without a Prescription and Naloxone Dispensing Rates.
    Gangal NS; Hincapie AL; Jandarov R; Frede SM; Boone JM; MacKinnon NJ; Koechlin K; DeFiore-Hyrmer J; Holthusen A; Heaton PC
    JAMA Netw Open; 2020 Jan; 3(1):e1920310. PubMed ID: 32003819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in Naloxone Prescriptions Dispensed in US Retail Pharmacies Since 2013.
    Jones CM; Lurie PG; Compton WM
    Am J Public Health; 2016 Apr; 106(4):689-90. PubMed ID: 26890174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between state Medicaid expansion status and naloxone prescription dispensing.
    Sohn M; Talbert JC; Delcher C; Hankosky ER; Lofwall MR; Freeman PR
    Health Serv Res; 2020 Apr; 55(2):239-248. PubMed ID: 32030751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in State-Level Pharmacy-Based Naloxone Dispensing Rates, 2012-2019.
    Guy GP; Khushalani JS; Jackson H; Sims RSC; Arifkhanova A
    Am J Prev Med; 2021 Dec; 61(6):e289-e295. PubMed ID: 34801208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration.
    Bounthavong M; Devine EB; Christopher MLD; Harvey MA; Veenstra DL; Basu A
    Health Serv Res; 2019 Oct; 54(5):1055-1064. PubMed ID: 31313839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies.
    Spivey CA; Wilder A; Chisholm-Burns MA; Stallworth S; Wheeler J
    J Am Pharm Assoc (2003); 2020; 60(5):694-701.e1. PubMed ID: 32146134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Naloxone by Payer Type.
    Jiang X; Strahan AE; Zhang K; Guy GP
    JAMA; 2024 Feb; 331(8):700-702. PubMed ID: 38285437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing Naloxone Access and Prescribing for Patients on High-Dose Opioids From a Managed Care Pharmacy Health Plan Perspective.
    Hansgen JP; Robertson ML; Verzino EM; Manning LM
    J Pharm Pract; 2024 Dec; 37(6):1291-1296. PubMed ID: 38685768
    [No Abstract]   [Full Text] [Related]  

  • 15. Retrospective study investigating naloxone prescribing and cost in US Medicaid and Medicare patients.
    Manko CD; Ahmed MS; Harrison LR; Kodavatiganti SA; Lugo N; Konadu JO; Khan F; Massari CA; Sealey TK; Addison ME; Mbah CN; McCall KL; Fraiman JB; Piper BJ
    BMJ Open; 2024 May; 14(5):e078592. PubMed ID: 38692729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
    Carroll NV
    J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies.
    Xu J; Davis CS; Cruz M; Lurie P
    Drug Alcohol Depend; 2018 Aug; 189():37-41. PubMed ID: 29860058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicaid prescription limits and their implications for naloxone accessibility.
    Roberts AW; Look KA; Trull G; Carpenter DM
    Drug Alcohol Depend; 2021 Jan; 218():108355. PubMed ID: 33309522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing landscape of naloxone availability in the United States, 2011 - 2017.
    Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
    Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.